Publications by authors named "Hanmei Lou"
Article Synopsis
- Brain metastasis from cervical cancer is rare and has a poor prognosis, with no established effective treatments known until recently.
- A 50-year-old patient with cervical cancer developed multiple metastases and initially received various therapies, but with limited success.
- After starting treatment with the PD-1/CTLA-4 inhibitor cadonilimab, the patient showed significant improvement, achieving a very good partial response and surviving over 18 months after the brain metastasis diagnosis.
Article Synopsis
- - Metastasis is a major concern in cervical cancer (CC), particularly affecting lymph nodes and lungs, leading to poor patient outcomes and limited predictive tools for determining metastasis risk.
- - The study analyzed plasma samples from CC patients with and without metastasis using advanced proteomics and metabolomics techniques, revealing common inflammatory processes and distinct metabolic changes between lung and lymph node metastasis groups.
- - Researchers identified two promising biomarker panels for predicting lung and lymph node metastasis, demonstrating strong diagnostic potential with high accuracy in both training and testing sets.
Article Synopsis
- * In this phase 3, double-blind trial, 445 women were randomly assigned to receive either cadonilimab with chemotherapy or a placebo with chemotherapy, with results measured over time for progression-free and overall survival.
- * Findings showed that patients receiving cadonilimab experienced a median progression-free survival of 12.7 months compared to 8.1 months for the placebo group, along with improved overall survival,
Article Synopsis
- * Out of 71 patients, the objective response rate (ORR) was 9.9%, with a disease control rate of 36.6% and a median duration of response of 10.7 months.
- * The treatment was associated with a significant incidence of adverse events, with 73.2% reporting treatment-related complications, but overall, iparomlimab demonstrated preliminary efficacy and a manageable safety profile.
Article Synopsis
- - The study aimed to assess the effectiveness of rhSOD enemas in reducing radiation-induced acute rectal injury (RARI) among patients with locally advanced cervical cancer undergoing chemoradiation therapy.
- - Conducted in a phase 3 clinical trial across 14 medical centers in China, it found that patients using rhSOD enemas experienced significantly fewer days of diarrhea (both ≥G1 and ≥G2) compared to those who did not use the enema.
- - Overall, while some patients reported side effects, the use of rhSOD enemas led to a notable decrease in the severity and incidence of diarrhea and a trend towards lower RARI grades among patients.
Purpose: Immune checkpoint inhibitors (ICI) have been a potential treatment option for patients with cervical cancer in several clinical studies. We investigated the safety and efficacy of cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4, plus standard therapy for the first-line treatment of R/M CC (recurrent and/or metastatic cervical cancer).
Patients And Methods: Eligible patients were assigned to 3 cohorts: cohort A-15 (cadonilimab 15 mg/kg every 3 weeks (Q3W) plus chemotherapy), cohort A-10 (cadonilimb 10 mg/kg Q3W plus chemotherapy), and cohort B-10 (cadonilimab 10 mg/kg Q3W plus chemotherapy and bevacizumab).
Article Synopsis
- The study investigates the relationship between immune status and cancer prognosis, emphasizing the understudied role of the stromal environment in tumors across 12 cancer types from TCGA.
- Using ESTIMATE to assess stromal and immune scores in 6193 tumor samples, researchers found that stromal scores were more predictive of patient outcomes in most cancer types compared to immune scores.
- The findings suggest that while high immune scores often indicate better prognosis, this isn't true for all cancers; hence, combining stromal and immune assessments could enhance prognostic accuracy.
Article Synopsis
- Immune checkpoint inhibitors like PD-1 and CTLA-4 have shown effectiveness in treating various cancers, prompting the study of cadonilimab, a bispecific antibody for patients with advanced solid tumors.
- This multicenter trial in China included patients with specific eligibility criteria, assessing cadonilimab's safety and effectiveness through different dosage phases across cancers like cervical, esophageal, and liver cancer.
- The primary focus was on determining safety during phase 1b and the objective response rate in phase 2, with results being documented and registered under ClinicalTrial.gov, indicating the study has concluded.
Article Synopsis
- The study focused on the distribution of HPV infections in patients with early-stage cervical squamous cell carcinoma (CSCC) and examined the correlation between high-risk HPV infections, clinicopathological factors, and patient survival rates.
- Out of 1425 patients studied, 84.3% were found to be infected with HPV, mainly the high-risk type (82.6%), with HPV16 being the most common subtype (65.1%).
- Results indicated that while factors like deep stromal invasion, lymphovascular space invasion (LVSI), and lymph node metastasis were significant predictors of 5-year overall survival, high-risk HPV infection status itself did not predict survival outcomes.
Article Synopsis
- This study investigates the relationship between vaginal microbiota and HPV-related cervical disease (HRCD) by analyzing samples from 98 patients with HRCD and 58 healthy controls in Hangzhou.
- It finds that the diversity of vaginal microbiota is significantly higher in HRCD patients, with Firmicutes as the dominant phylum and Lactobacillus showing the most notable changes between the two groups.
- A random forest algorithm was used to develop a diagnostic model that accurately predicts HRCD, achieving a high area under the curve (89.7%), with validation in additional cohorts confirming its effectiveness.
Background And Purpose: Dose escalation for positive node maybe improve the regional control of patients with node-positive cervical cancer, but the optimal dose for nodes of different sizes remains controversial. The purpose of this study was to explore the individualized dose escalation for lymph nodes (LNs) with different sizes in the definitive radiotherapy of cervical cancer.
Methods: A total of 1002 cervical cancer patients with the International Federation of Gynecology and Obstetrics (FIGO 2009) stage IB1-IVA, who were treated by definitively radiotherapy between September 2013 and December 2016 were enrolled.
Article Synopsis
- A phase I study was conducted on SHR-1701, a new treatment for recurrent or metastatic cervical cancer patients who had limited options after platinum-based therapies, focusing on effectiveness and safety.
- Out of 32 enrolled patients, the objective response rate (ORR) was 15.6%, while 50% experienced disease stabilization, with some responses ongoing after treatment; the median progression-free survival (PFS) was 2.7 months.
- The results suggest that SHR-1701 shows promising anti-tumor activity and manageable safety, offering a potential new treatment avenue for this patient population.
Article Synopsis
- The study aimed to assess the relationship between pretreatment maximum standardized F-fluorodeoxyglucose uptake value (SUV) and serum squamous cell carcinoma antigen (SCC-ag) with FIGO2018 stages and prognosis in women with advanced squamous cervical cancer.
- Researchers analyzed data from 116 women treated between 2013-2015 in China, finding significant differences in menopause status, FIGO2018 stages, and survival rates based on SUV levels.
- High SUV and SCC-ag levels were linked to worse prognosis, indicating that both metrics could be important indicators for predicting outcomes in squamous cervical cancer.
Article Synopsis
- The study aimed to compare the outcomes of patients with adenocarcinoma (AC) and adenosquamous carcinoma (ASC) in stage IB-IIA cervical cancer following radical hysterectomy.
- The analysis involved 370 patients and found no significant differences in overall survival between the two cancer types, although ASC patients tended to be older and had higher rates of certain tumor markers and invasion.
- For intermediate-risk ASC patients, concurrent chemoradiotherapy improved survival, whereas such treatment did not show benefits in AC patients, highlighting the importance of serum tumor markers for personalized treatment strategies.
Article Synopsis
- The study investigates how plasmacytoid dendritic cells (pDCs) change when exposed to HPV E6 and co-cultured with Caski cervical cancer cells, to understand their role in cancer development.
- Results show that HPV E6 increases the expression of certain markers (CD40, MyD88, TRAF6) in pDCs, but when co-cultured with Caski cells, these markers are expressed at lower levels.
- The findings suggest that pDCs may influence cervical cancer development through regulation of CD40, but more research is needed to clarify the underlying mechanisms.
Objective: This study aimed to investigate the clinical and histological features affecting the survival of patients with early cervical squamous cell cancer treated with radical hysterectomy.
Methods: We retrospectively analyzed clinical and histological data for patients with stage IB-IIA cervical cancer treated by radical hysterectomy at Zhejiang Cancer Hospital from August 2008 to January 2013.
Results: A total of 1435 patients were included in the study.
Article Synopsis
- The study aimed to explore how different sites and numbers of metastases affect survival rates in patients newly diagnosed with cervical cancer.
- The research involved reviewing medical records of 99 patients and found that the median overall survival time was 11.7 months, with significant differences in survival related to the type and number of metastases.
- Key findings showed that liver metastasis was linked to significantly worse survival, highlighting the need for personalized treatment approaches based on metastatic sites.
Article Synopsis
- The study examined the presence of specific regulatory T cells (Tregs) in the blood of 82 women with endometrioid adenocarcinoma (EA) to understand their role in cancer immunity.
- Results showed that Tregs constituted a higher percentage of CD4 T cells in EA patients compared to healthy women, but no differences were found based on cancer stage or patient demographics.
- The Tregs produced high levels of IL-10 (an immunosuppressive cytokine) without significant differences in the overall immune activity between EA patients and healthy controls, suggesting that Tregs might promote immune tolerance in endometrial cancer.
Article Synopsis
- A retrospective study was conducted to evaluate the effectiveness of definitive pelvic radiotherapy combined with chemotherapy in patients diagnosed with organ metastatic cervical cancer, addressing its unclear clinical efficacy.
- The study analyzed 48 patients treated at Zhejiang Cancer Hospital from 2006 to 2016, comparing two treatment groups: one receiving combined radiotherapy and chemotherapy, and the other receiving chemotherapy alone or palliative radiotherapy.
- Results indicated that the group receiving chemotherapy with definitive pelvic radiotherapy had a median overall survival of 17.3 months, significantly better than 10 months for the other group, with treatment failure primarily due to the progression of distant metastatic lesions.
Background: Neuroendocrine cervical carcinoma (NECC) is a rare but aggressive form of cervical cancer representing less than 3% of all cervical cancer cases. The objective of this study is to evaluate the effects of the clinicopathologic features and treatment modalities on the survival of patients with NECC.
Methods: In all, 89 stage I-IV patients with NECC that were diagnosed and treated between 2006 and 2014 at the Zhejiang Cancer Hospital were retrospectively recruited in this study.
Postoperative clinicopathological factors affecting cervical adenocarcinoma: Stages I-IIB.
Medicine (Baltimore)
January 2018
Article Synopsis
- Currently, cervical adenocarcinoma (ADC) is treated the same way as squamous cell carcinoma, but this approach may not be effective for ADC, prompting this study to explore its postoperative prognosis in stage I-IIB patients.
- The study analyzed data from 312 patients who had radical hysterectomy and revealed 5-year overall survival (OS) and relapse-free survival (RFS) rates of 88.2% and 83.8%, respectively, with recurrence occurring in 35 women mainly in the pelvis, vaginal stump, and lungs.
- Key findings identified the number of positive pelvic nodes and age at surgery as significant factors influencing survival, while larger postoperative tumor diameter (≥4 cm) was emphasized as an
Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma.
Int J Gynecol Cancer
November 2017
Objective: This study aims to explore the feasibility of a hysteroscopic procedure combined with progestin therapy in young patients with stage Ia endometrioid carcinoma (EC) to avoid sterilization.
Materials And Methods: Eleven young women with stage Ia EC (International Federation of Gynecology and Obstetrics grade 1) who were treated with a hysteroscopic approach combined with progestin from July 2004 to June 2016 were retrospectively analyzed and followed up to monitor their general recovery and pregnancy outcome.
Results: The patients' median age was 27.
Article Synopsis
- An increase in cervical adenocarcinoma (ADC) cases has led to common practices of removing ovaries during treatment, potentially affecting the quality of life for young women.
- A study analyzed 312 patients with early-stage cervical ADC, finding that only 4.5% developed ovarian metastases, and certain factors like uterine involvement were linked to the risk.
- The findings suggest that preserving ovaries may be safe in early-stage ADC patients without significant tumor invasion, allowing for better quality of life while maintaining treatment efficacy.
Article Synopsis
- HPV is the main cause of cervical cancer, and current vaccines primarily target HPV types 16 and 18, which may not be adequate for regions like China due to different HPV genotype distributions.
- A study of 5,410 women with cervical cancer found that HPV-16 and -18 were responsible for significant percentages of various cancer types, but low-risk types included in the vaccine were less effective.
- Adding HPV types 52 and 58 to the vaccine could enhance protection against cervical cancer and pre-cancerous conditions, suggesting a need for a more tailored vaccine for better efficacy in the Zhejiang Province.
[Association between metabolic syndrome and prognosis of endometrioid carcinoma].
Zhonghua Fu Chan Ke Za Zhi
October 2014
Article Synopsis
- The study aimed to investigate the link between metabolic syndrome (MS) and the prognosis of patients with endometrioid carcinoma, utilizing data from 256 patients treated at Zhejiang Cancer Hospital from 2001 to 2008.
- The research found a significant difference in survival rates between patients with and without MS, with those having MS showing lower survival rates and shorter survival times.
- Results indicated that factors associated with MS, such as high body mass index, abnormal blood pressure, and elevated glucose levels, were correlated with poorer outcomes for endometrioid carcinoma patients.